UCB is a global biopharmaceutical company dedicated to discovering and developing treatments that aim to elevate the lives of people living with neurological and immunological conditions, as well as rare diseases.
The UK represents one of our three global R&D hubs, employing approximately 10% of UCB's global workforce across national, regional, and global roles.
We put patients at the centre of everything we do, which is why we reinvest around 25% of our revenue into biopharmaceutical R&D and employ world-class scientists who focus on translating our research into therapies.
